<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="jeo270144" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Exp Orthop</journal-id><journal-id journal-id-type="iso-abbrev">J Exp Orthop</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2197-1153</journal-id><journal-id journal-id-type="publisher-id">JEO2</journal-id><journal-title-group><journal-title>Journal of Experimental Orthopaedics</journal-title></journal-title-group><issn pub-type="epub">2197-1153</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39830171</article-id><article-id pub-id-type="pmc">PMC11739897</article-id>
<article-id pub-id-type="doi">10.1002/jeo2.70144</article-id><article-id pub-id-type="publisher-id">JEO270144</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Paper</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Arthroscopic debridement followed by intra&#x02010;articular injection of micro&#x02010;fragmented adipose tissue in patients affected by knee osteoarthritis: Clinical results up to 48 months from a prospective clinical study</article-title></title-group><contrib-group><contrib id="jeo270144-cr-0001" contrib-type="author"><name><surname>Bruno</surname><given-names>Andrea Antonio Maria</given-names></name><xref rid="jeo270144-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jeo270144-cr-0002" contrib-type="author" corresp="yes"><name><surname>Anzillotti</surname><given-names>Giuseppe</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9327-5350</contrib-id><xref rid="jeo270144-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jeo270144-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>doc.anzillotti@gmail.com</email></address></contrib><contrib id="jeo270144-cr-0003" contrib-type="author"><name><surname>De Donato</surname><given-names>Massimo</given-names></name><xref rid="jeo270144-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jeo270144-cr-0004" contrib-type="author"><name><surname>Basso</surname><given-names>Marco</given-names></name><xref rid="jeo270144-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jeo270144-cr-0005" contrib-type="author"><name><surname>Tamini</surname><given-names>Jacopo</given-names></name><xref rid="jeo270144-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jeo270144-cr-0006" contrib-type="author"><name><surname>Dupplicato</surname><given-names>Paolo</given-names></name><xref rid="jeo270144-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jeo270144-cr-0007" contrib-type="author"><name><surname>Kon</surname><given-names>Elizaveta</given-names></name><xref rid="jeo270144-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jeo270144-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jeo270144-cr-0008" contrib-type="author"><name><surname>Di Matteo</surname><given-names>Berardo</given-names></name><xref rid="jeo270144-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jeo270144-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="jeo270144-cr-0009" contrib-type="author"><name><surname>Arnaldi</surname><given-names>Enrico</given-names></name><xref rid="jeo270144-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="jeo270144-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>IRCCS Humanitas Research Hospital</institution>
<city>Rozzano</city>
<named-content content-type="country-part">Milan</named-content>
<country country="IT">Italy</country>
</aff><aff id="jeo270144-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Biomedical Sciences</named-content>
<institution>Humanitas University</institution>
<city>Pieve Emanuele</city>
<named-content content-type="country-part">Milan</named-content>
<country country="IT">Italy</country>
</aff><aff id="jeo270144-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Traumatology</named-content>
<institution>Orthopaedics and Disaster Surgery, Sechenov University</institution>
<city>Moscow</city>
<country country="RU">Russia</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold> Giuseppe Anzillotti, Department of Biomedical Sciences, Humanitas University, Milan, Italy.<break/>
Email: <email>doc.anzillotti@gmail.com</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2025</year></pub-date><volume>12</volume><issue seq="67">1</issue><issue-id pub-id-type="doi">10.1002/jeo2.v12.1</issue-id><elocation-id>e70144</elocation-id><history>
<date date-type="rev-recd"><day>18</day><month>11</month><year>2024</year></date>
<date date-type="received"><day>19</day><month>8</month><year>2024</year></date>
<date date-type="accepted"><day>21</day><month>11</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 The Author(s). Journal of Experimental Orthopaedics published by John Wiley & Sons Ltd on behalf of European Society of Sports Traumatology, Knee Surgery and Arthroscopy.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Journal of Experimental Orthopaedics</italic> published by John Wiley &#x00026; Sons Ltd on behalf of European Society of Sports Traumatology, Knee Surgery and Arthroscopy.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:JEO2-12-e70144.pdf"/><abstract><title>Abstract</title><sec id="jeo270144-sec-0010"><title>Purpose</title><p>Micro&#x02010;fragmented adipose tissue is emerging as a promising option for the treatment of various diseases including knee osteoarthritis (OA), though clinical trials are often limited by short follow&#x02010;up periods. Our aim was to evaluate the safety and clinical outcomes of an arthroscopic debridement followed by a single injection of micro&#x02010;fragmented adipose tissue in patients affected by knee OA.</p></sec><sec id="jeo270144-sec-0020"><title>Methods</title><p>From 2016 to 2020, patients affected by knee OA were enroled. Micro&#x02010;fragmented adipose tissue was obtained through the Lipogems&#x000ae; kit and intraarticularly injected after an arthroscopic debridement. Visual analogue scale for pain, Tegner score, Knee Injury and Osteoarthritis Outcome score subscales variations were assessed from baseline to 3, 6, 12, 24 and 48 months of follow&#x02010;up.</p></sec><sec id="jeo270144-sec-0030"><title>Results</title><p>Forty&#x02010;one patients were evaluated up to 6 months of follow&#x02010;up, 39 patients up to 24 months of follow&#x02010;up and 38 patients up to 48 months of follow&#x02010;up. Three underwent knee replacement surgery during the time of the study. All the clinical scores analyzed achieved statistically significant changes up to the last follow&#x02010;up.</p></sec><sec id="jeo270144-sec-0040"><title>Conclusions</title><p>A single intra&#x02010;articular knee injection of micro&#x02010;fragmented adipose tissue following arthroscopic debridement is able to provide significant clinical benefits in patients affected by knee OA up to 4 years of follow&#x02010;up.</p><p>The present clinical study was registered on <ext-link xlink:href="https://clinicaltrials.gov" ext-link-type="uri">clinicaltrials.gov</ext-link> (no. NCT06545266).</p></sec><sec id="jeo270144-sec-0050"><title>Level of Evidence</title><p>Level IV case series.</p></sec></abstract><kwd-group><kwd id="jeo270144-kwd-0001">adipose&#x02010;derived stem cells</kwd><kwd id="jeo270144-kwd-0002">arthroscopy</kwd><kwd id="jeo270144-kwd-0003">knee</kwd><kwd id="jeo270144-kwd-0004">mesenchymal stem cells</kwd><kwd id="jeo270144-kwd-0005">osteoarthritis</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>None</funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="3"/><page-count count="10"/><word-count count="5826"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:27.02.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jeo270144-cit-0045">
<string-name>
<surname>Bruno</surname>, <given-names>A. A. M.</given-names>
</string-name>, <string-name>
<surname>Anzillotti</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>De Donato</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Basso</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Tamini</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Dupplicato</surname>, <given-names>P.</given-names>
</string-name> et al. (<year>2025</year>) <article-title>Arthroscopic debridement followed by intra&#x02010;articular injection of micro&#x02010;fragmented adipose tissue in patients affected by knee osteoarthritis: Clinical results up to 48 months from a prospective clinical study</article-title>. <source>Journal of Experimental Orthopaedics</source>, <volume>12</volume>, <elocation-id>e70144</elocation-id>. <pub-id pub-id-type="doi">10.1002/jeo2.70144</pub-id>
<pub-id pub-id-type="pmid">39830171</pub-id>
</mixed-citation>
</p></notes></front><body><def-list list-content="abbreviations"><title>Abbreviations</title><def-item><term>FDA</term><def><p>Food and Drug Administration</p></def></def-item><def-item><term>KL</term><def><p>Kellgren&#x02013;Lawrence</p></def></def-item><def-item><term>KOOS</term><def><p>Knee Injury and Osteoarthritis Outcome</p></def></def-item><def-item><term>MSC</term><def><p>mesenchymal stem cell</p></def></def-item><def-item><term>OA</term><def><p>osteoarthritis</p></def></def-item><def-item><term>QoL</term><def><p>quality of life</p></def></def-item><def-item><term>VAS</term><def><p>visual analogue scale</p></def></def-item></def-list><sec id="jeo270144-sec-0060"><title>INTRODUCTION</title><p>Osteoarthritis (OA) is a whole joint disease which very commonly affects the knee joint [<xref rid="jeo270144-bib-0003" ref-type="bibr">3</xref>]. After low back pain, knee OA is considered the second musculoskeletal disorder in disability&#x02010;adjusted life years for the adult population [<xref rid="jeo270144-bib-0036" ref-type="bibr">36</xref>, <xref rid="jeo270144-bib-0037" ref-type="bibr">37</xref>]. Its burden has a dramatic impact on the healthcare system, with esteemed direct and indirect costs approximately up to 2.5% of one country's domestic product [<xref rid="jeo270144-bib-0016" ref-type="bibr">16</xref>, <xref rid="jeo270144-bib-0023" ref-type="bibr">23</xref>, <xref rid="jeo270144-bib-0024" ref-type="bibr">24</xref>].</p><p>Conservative treatments, such as oral anti&#x02010;inflammatories or intra&#x02010;articular viscosupplementation, may be useful as symptomatic relief in earlier stages [<xref rid="jeo270144-bib-0018" ref-type="bibr">18</xref>, <xref rid="jeo270144-bib-0021" ref-type="bibr">21</xref>], but there is no effect on disease progression. The ultimate treatment for knee OA still consists of total joint arthroplasty, though it still suffers from biological complications (i.e., infections) and mechanical alterations (i.e., material wearing, loosening or mobilization) [<xref rid="jeo270144-bib-0005" ref-type="bibr">5</xref>, <xref rid="jeo270144-bib-0020" ref-type="bibr">20</xref>]. Given these limitations, new conservative approaches are emerging to postpone as much as possible the prosthetic implantation. Cartilage repair procedures are able to provide clinical benefits in patients suffering from well&#x02010;delimited cartilage lesions; however, they are not indicated for patients suffering from diffuse knee OA [<xref rid="jeo270144-bib-0002" ref-type="bibr">2</xref>, <xref rid="jeo270144-bib-0014" ref-type="bibr">14</xref>, <xref rid="jeo270144-bib-0017" ref-type="bibr">17</xref>]. Corticosteroid injections may be indicated in cases of diffuse diseases, even though their effects could range from detrimental to disease&#x02010;modifying [<xref rid="jeo270144-bib-0007" ref-type="bibr">7</xref>]. Orthobiologics have seen their fortune in the last 20 years as the most innovative therapies available on the market. In particular, mesenchymal stem cells (MSCs) are being investigated as the holder for the anti&#x02010;inflammatory effect inside the joint, able to attenuate the OA symptoms, hence recently deserving the title of &#x02018;medicinal signalling cells&#x02019; [<xref rid="jeo270144-bib-0011" ref-type="bibr">11</xref>, <xref rid="jeo270144-bib-0012" ref-type="bibr">12</xref>, <xref rid="jeo270144-bib-0027" ref-type="bibr">27</xref>]. Furthermore, the &#x02018;secretome effect&#x02019; also includes the intraarticular release of numerous growth factors (i.e., HIF&#x02014;hypoxia&#x02010;inducible factor, bFGF&#x02014;basic fibroblast growth factor, IGFs&#x02014;insulin&#x02010;like growth factors and VEGF&#x02014;vascular endothelial growth factor), stimulating chondrogenesis and MSCs proliferation itself [<xref rid="jeo270144-bib-0026" ref-type="bibr">26</xref>, <xref rid="jeo270144-bib-0032" ref-type="bibr">32</xref>]. Recent evidences on animals suggest that their role may not only be limited to a symptomatic or functional impact but they could also serve as disease&#x02010;modified drugs [<xref rid="jeo270144-bib-0009" ref-type="bibr">9</xref>, <xref rid="jeo270144-bib-0034" ref-type="bibr">34</xref>]. Recent clinical trials have confirmed these results in humans, demonstrating reduction of pain and increased functional improvement [<xref rid="jeo270144-bib-0033" ref-type="bibr">33</xref>, <xref rid="jeo270144-bib-0042" ref-type="bibr">42</xref>]. Interestingly, a recent trial by Cattaneo et al. proved a significant improvement in KOOS score in patients affected by knee OA, undergone chondral shaving associated with micro&#x02010;fragmented adipose tissue knee injection [<xref rid="jeo270144-bib-0013" ref-type="bibr">13</xref>]. Nonetheless, this evidence is limited by short follow&#x02010;up, which limits the impact of such findings. Accordingly, the aim of the present study was to evaluate the reduction in pain, effects on functional scores and safety of an arthroscopic debridement followed by a single injection of micro&#x02010;fragmented adipose tissue in patients affected by knee OA at longer follow&#x02010;ups.</p></sec><sec sec-type="materials-and-methods" id="jeo270144-sec-0070"><title>MATERIALS AND METHODS</title><sec id="jeo270144-sec-0080"><title>Patients' selection</title><p>The present clinical study was registered on <ext-link xlink:href="https://clinicaltrials.gov" ext-link-type="uri">clinicaltrials.gov</ext-link> (no. NCT06545266). From 2016 to 2020, a total of 41 patients with different degrees of knee OA were prospectively enroled for this study. The internal ethical committee of the Humanitas Research Hospital, Milan, Italy approved the present study (study no. 2219). A written informed consent was obtained from each patient prior to enrolment.</p><p>Inclusion criteria were: age &#x0003e;18 years, patients affected by radiologically confirmed knee OA according to Kellgren&#x02013;Lawrence (KL) classification (Grades I&#x02013;IV), not responsive to previous standard conservative treatments (i.e., physical therapy, exercise, oral pharmacological treatment and intra&#x02010;articular injections of corticosteroids/hyaluronic acid), with symptoms in the index knee persisting for at least three consecutive months at the moment of study enrolment.</p><p>Exclusion criteria were as follows: recent traumatic events involving the index joint, chondromatosis, intra&#x02010;articular injections of any type in the previous 6 months, malignancy, pregnancy, patients on anticoagulant therapy or suffering from coagulopathies and related disorders, systematic disorders affecting the joints (i.e., rheumatoid arthritis). Enroled patients underwent a knee radiograph (antero&#x02010;posterior, Rosenberg and lateral projections) as well as magnetic resonance imaging before the procedure to stage knee OA and evaluate potential intra&#x02010;articular loose bodies or diseases different from knee OA (e.g., tumours or focal cartilage lesions).</p></sec><sec id="jeo270144-sec-0090"><title>Surgical procedure</title><p>Patients were placed in a supine position and Betadine was used to treat the abdomen. Anaesthesia was performed using disposable blunted cannulas with a modified Klein solution (a mixture of 250&#x02009;mL of saline solution [4&#x000b0;C], 50&#x02009;mL of lidocaine [2%] and 1&#x02009;mL of epinephrine, 1:1000). Two skin incisions of approximately 0.5&#x02009;cm were performed on both sides of the abdomen and the solution was injected in the subcutaneous fat tissue. Tissue harvesting was performed, connecting the VacLock&#x000ae; vacuum syringe to an aspiration blunt cannula. Approximately the same quantity of tissue was harvested from each side of the patient's abdomen, with a minimum of 100&#x02009;ml. All procedures were performed by at least two physicians the first physician prepared and used the Lipogems&#x000ae; ortho kit, and the other performed a debridement arthroscopic procedure on the selected knee in order to exclude the presence of other causes of pain (e.g., loose bodies and meniscal flaps). The debridement procedure consisted of the removal of eventual chondral flaps and the regularization of eventual degenerative meniscal lesions.</p><p>Once the aspiration process was completed, approximately 100&#x02009;mL of lipoaspirate was processed each time in the standard 225&#x02009;mL device. The Lipogems&#x000ae; ortho kit is made by a core, a simple disposable device that progressively reduces in size the clusters of adipose tissue (from 1 to 3.5&#x02009;mm to clusters of approximately 0.2&#x02013;0.8&#x02009;mm) while at the same time eliminating oil and blood residues. After the appropriate tissue preparation, the final Lipogems&#x000ae; product was ready to be collected in 10&#x02009;mL syringes from the upper opening and ready for its knee intra&#x02010;articular injection at the level of the superolateral edge of the patella. This process required approximately 20&#x02009;min. and the final product volume obtained was roughly 25%&#x02013;30% of the initial tissue that was harvested. Skin portals were sutured and elastic body belt was applied and maintained for 10 days. Patients were usually discharged the same day of the procedure with a post&#x02010;operative pain management protocol (Paracetamol 1000&#x02009;mg 1 tablet three times a day for 5 days and Ibuprofen 600&#x02009;mg 1 tablet twice a day for 2 days) and a thromboembolic prophylaxis protocol (low molecular weight heparin for 1 week). Crutches were suggested for the first two days, and full weight bearing was allowed from the first post&#x02010;operative day.</p></sec><sec id="jeo270144-sec-0100"><title>Clinical assessments</title><sec id="jeo270144-sec-0110"><title>Primary outcome</title><p>Visual analogue scale (VAS) for pain variation from baseline to 3, 6, 12, 24 and 48 months of follow&#x02010;up.</p></sec><sec id="jeo270144-sec-0120"><title>Secondary outcomes</title><p>The Tegner score and Knee Injury and Osteoarthritis Outcome (KOOS) score subscales assess variations from baseline to 3, 6, 12, 24 and 48 months of follow&#x02010;up, the safety of the procedure and the failure rate.</p><p>Moreover, results from clinical scores were also stratified according to three age groups (&#x0003c;50, between 50 and 60 and &#x0003e;60 years).</p><p>Data were also stratified and analyzed with respect to the OA grading classification KL scale, dividing patients into mild OA (K&#x02010;L1).</p></sec></sec><sec id="jeo270144-sec-0130"><title>Failures</title><p>Treatment failure was defined as any surgical treatment performed on the index knee during the study period.</p></sec><sec id="jeo270144-sec-0140"><title>Statistical analysis</title><p>Data were described as number and percentage, if categorical, or mean and standard deviation if continuous. Change of SCALE within time was explored with multilevel mixed&#x02010;effects regression. Estimates were also adjusted by age and KL scale, and stratified by age divided in decades, and KL, dichotomized as Grades I and II versus Grades III and IV.</p><p>All analyses were made with Stata17 programme. A <italic toggle="yes">p&#x02009;&#x0003c;&#x02009;</italic>0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="jeo270144-sec-0150"><title>RESULTS</title><p>A total of 41 patients were enroled in the present study. 41 patients were evaluated up to 6 months of follow&#x02010;up, 39 patients up to 24 months of follow&#x02010;up and 38 patients up to the 48 months (final) of follow&#x02010;up. Twenty&#x02010;six patients were males and 15 were females. Five patients were KL Grade I, 16 patients were KL Grade II, 18 patients were KL Grade III and 2 patients were KL Grade IV. Characteristics of the included patients are listed in Table&#x000a0;<xref rid="jeo270144-tbl-0001" ref-type="table">1</xref>.</p><table-wrap position="float" id="jeo270144-tbl-0001" content-type="Table"><label>Table 1</label><caption><p>Demographic characteristics of the included patients.</p></caption><table frame="hsides" rules="groups"><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000" valign="bottom"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Value (<italic toggle="yes">N</italic>&#x02009;=&#x02009;41)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="left" valign="top" rowspan="1" colspan="1">61&#x02009;&#x000b1;&#x02009;9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender (female)</td><td align="left" valign="top" rowspan="1" colspan="1">15/41</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI</td><td align="left" valign="top" rowspan="1" colspan="1">28&#x02009;&#x000b1;&#x02009;4.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Index knee (right)</td><td align="left" valign="top" rowspan="1" colspan="1">25/41</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Kellgren&#x02013;Lawrence grade</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>
<list list-type="bullet"><list-item><p>I</p></list-item><list-item><p>II</p></list-item><list-item><p>III</p></list-item><list-item><p>IV</p></list-item></list>
</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>5/41</p>
<p>16/41</p>
<p>18/41</p>
<p>2/41</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Index knee (right)</td><td align="left" valign="top" rowspan="1" colspan="1">25/41</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Arthroscopic procedures performed</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>
<list list-type="bullet"><list-item><p>Debridement alone</p></list-item><list-item><p>Debridement + degenerative meniscal flaps removal</p></list-item><list-item><p>Debridement + loose body removal</p></list-item></list>
</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>36/41</p>
<p>3/41</p>
<p>2/41</p>
</td></tr></tbody></table><table-wrap-foot><fn id="jeo270144-tbl1-note-0001"><p>Abbreviation: BMI, body mass index.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>The average VAS pre&#x02010;operatively was 5.8&#x02009;&#x000b1;&#x02009;1.63. At 3 months, there was a statistically significant decrease to 2.22&#x02009;&#x000b1;&#x02009;1.4 (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05) and remained stable at 6 and 12 months to then slightly increase to an average of 2.89&#x02009;&#x000b1;&#x02009;1.64 at the end of the study (Figure&#x000a0;<xref rid="jeo270144-fig-0001" ref-type="fig">1</xref>).</p><fig position="float" fig-type="Figure" id="jeo270144-fig-0001"><label>Figure 1</label><caption><p>Evaluation of visual analogue scale (VAS) for pain at 3, 6, 12 and 48 months of follow&#x02010;up. On the plot, values from top to bottom are maximum, 75th percentile, median, 25th percentile and minimum.*Statistically significant (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05) compared to baseline.</p></caption><graphic xlink:href="JEO2-12-e70144-g002" position="anchor" id="jats-graphic-1"/></fig><p>The average TEGNER score pre&#x02010;operatively was 70.9&#x02009;&#x000b1;&#x02009;8.9 and appeared to be marginally increased by a few points to a maximum average of 85.0&#x02009;&#x000b1;&#x02009;8.6 at 3 months, followed by a faint decrease to 82.3&#x02009;&#x000b1;&#x02009;8.0 at the end of the study (Figure&#x000a0;<xref rid="jeo270144-fig-0002" ref-type="fig">2</xref>).</p><fig position="float" fig-type="Figure" id="jeo270144-fig-0002"><label>Figure 2</label><caption><p>Evaluation of Tegner score 3, 6, 12 and 48 months of follow&#x02010;up. On the plot, values from top to bottom are maximum, 75th percentile, median, 25th percentile and minimum. *Statistically significant (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05) compared to baseline.</p></caption><graphic xlink:href="JEO2-12-e70144-g001" position="anchor" id="jats-graphic-3"/></fig><p>All the variations in KOOS subscales (symptoms, pain, activity of daily living, sports, quality of life [QoL]) reached the statistically significant (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05) at 3 months of follow&#x02010;up compared to baseline and maintained the improvements up to the last follow&#x02010;up, with no further statistically significant variations (Figure&#x000a0;<xref rid="jeo270144-fig-0003" ref-type="fig">3</xref>).</p><fig position="float" fig-type="Figure" id="jeo270144-fig-0003"><label>Figure 3</label><caption><p>Evaluation of KOOS subscales at 3, 6, 12 and 48 months of follow&#x02010;up. On the plot, values from top to bottom are maximum, 75th percentile, median, 25th percentile and minimum. *Statistically significant (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05) compared to baseline. KOOS, Knee Injury and Osteoarthritis Outcome.</p></caption><graphic xlink:href="JEO2-12-e70144-g003" position="anchor" id="jats-graphic-5"/></fig><p>When stratified for age groups, only patients in the group &#x0003e;60 years achieved statistically significant results in all clinical scales, except for KOOS symptoms (Table&#x000a0;<xref rid="jeo270144-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="jeo270144-tbl-0002" content-type="Table"><label>Table 2</label><caption><p>The multilevel mixed&#x02010;effects regression analysis represents the change in clinical scores during the follow&#x02010;up period. Results were stratified for age groups (&#x0003c;50, between 50 and 60 and &#x0003e;60 years).</p></caption><table frame="hsides" rules="groups"><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="char" char="(" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="char" char="." style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000" valign="bottom"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Preop</th><th align="left" valign="bottom" rowspan="1" colspan="1">3 months</th><th align="left" valign="bottom" rowspan="1" colspan="1">6 months</th><th align="left" valign="bottom" rowspan="1" colspan="1">12 months</th><th align="left" valign="bottom" rowspan="1" colspan="1">24 months</th><th align="left" valign="bottom" rowspan="1" colspan="1">48 months</th><th align="left" valign="bottom" rowspan="1" colspan="1">Coeff (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td colspan="9" align="left" valign="top" rowspan="1">Age&#x02009;&#x02264;&#x02009;50</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">16</td><td align="left" valign="top" rowspan="1" colspan="1">16</td><td align="left" valign="top" rowspan="1" colspan="1">16</td><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VAS</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">5.44&#x02009;&#x000b1;&#x02009;1.67</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">1.75&#x02009;&#x000b1;&#x02009;1.53</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">1.88&#x02009;&#x000b1;&#x02009;1.75</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">1.87&#x02009;&#x000b1;&#x02009;1.60</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">2.40&#x02009;&#x000b1;&#x02009;1.68</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">2.67&#x02009;&#x000b1;&#x02009;1.63</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">&#x02212;0.01 (&#x02212;0.02 to 0.01)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.348</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TEGNER</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">73.8&#x02009;&#x000b1;&#x02009;9.6</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">88.4&#x02009;&#x000b1;&#x02009;8.5</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">87.5&#x02009;&#x000b1;&#x02009;8.4</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">86.8&#x02009;&#x000b1;&#x02009;6.9</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">84.5&#x02009;&#x000b1;&#x02009;6.7</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">83.9&#x02009;&#x000b1;&#x02009;6.7</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.00 (&#x02212;0.06; 0.07)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.919</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KOOS symptoms</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">71.7&#x02009;&#x000b1;&#x02009;15.5</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">81.7&#x02009;&#x000b1;&#x02009;14.0</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">81.9&#x02009;&#x000b1;&#x02009;14.7</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">82.6&#x02009;&#x000b1;&#x02009;14.4</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">80.2&#x02009;&#x000b1;&#x02009;13.9</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">80.7&#x02009;&#x000b1;&#x02009;14.7</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.04 (&#x02212;0.03; 0.10)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.252</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KOOS pain</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">62.3&#x02009;&#x000b1;&#x02009;12.5</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">80.6&#x02009;&#x000b1;&#x02009;12.7</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">80.0&#x02009;&#x000b1;&#x02009;13.6</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">79.6&#x02009;&#x000b1;&#x02009;14.0</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">76.7&#x02009;&#x000b1;&#x02009;13.5</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">76.5&#x02009;&#x000b1;&#x02009;14.3</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.03 (&#x02212;0.05; 0.11)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.436</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KOOS ADL</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">64.0&#x02009;&#x000b1;&#x02009;12.0</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">78.0&#x02009;&#x000b1;&#x02009;11.8</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">78.1&#x02009;&#x000b1;&#x02009;13.2</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">78.8&#x02009;&#x000b1;&#x02009;13.1</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">76.1&#x02009;&#x000b1;&#x02009;13.6</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">76.6&#x02009;&#x000b1;&#x02009;14.3</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.05 (&#x02212;0.02; 0.12)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.152</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KOOS sport</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">57.5&#x02009;&#x000b1;&#x02009;16.5</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">73.8&#x02009;&#x000b1;&#x02009;15.5</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">73.1&#x02009;&#x000b1;&#x02009;16.4</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">73.7&#x02009;&#x000b1;&#x02009;13.7</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">71.7&#x02009;&#x000b1;&#x02009;14.8</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">71.7&#x02009;&#x000b1;&#x02009;15.8</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.05 (&#x02212;0.03; 0.13)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.218</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KOOS QoL</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">59.0&#x02009;&#x000b1;&#x02009;15.5</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">73.0&#x02009;&#x000b1;&#x02009;16.1</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">74.2&#x02009;&#x000b1;&#x02009;14.6</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">73.3&#x02009;&#x000b1;&#x02009;13.0</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">70.8&#x02009;&#x000b1;&#x02009;13.7</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">71.7&#x02009;&#x000b1;&#x02009;15.4</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.04 (&#x02212;0.04; 0.12)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.313</td></tr><tr><td colspan="9" align="left" valign="top" rowspan="1">50 &#x0003c;&#x02009;Age &#x02264;&#x02009;60</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VAS</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">5.60&#x02009;&#x000b1;&#x02009;1.55</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">2.00&#x02009;&#x000b1;&#x02009;1.20</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">2.00&#x02009;&#x000b1;&#x02009;2.04</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">2.07&#x02009;&#x000b1;&#x02009;1.94</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">2.79&#x02009;&#x000b1;&#x02009;1.97</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">2.85&#x02009;&#x000b1;&#x02009;1.72</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">&#x02212;0.00 (&#x02212;0.02 to 0.01)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.699</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TEGNER</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">69.9&#x02009;&#x000b1;&#x02009;8.7</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">85.3&#x02009;&#x000b1;&#x02009;8.0</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">86.0&#x02009;&#x000b1;&#x02009;10.3</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">84.6&#x02009;&#x000b1;&#x02009;11.5</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">82.0&#x02009;&#x000b1;&#x02009;11.1</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">83.4&#x02009;&#x000b1;&#x02009;9.3</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.02 (&#x02212;0.04 to 0.09)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.502</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KOOS symptoms</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">64.0&#x02009;&#x000b1;&#x02009;10.2</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">76.2&#x02009;&#x000b1;&#x02009;10.7</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">77.9&#x02009;&#x000b1;&#x02009;14.2</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">77.8&#x02009;&#x000b1;&#x02009;11.9</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">75.0&#x02009;&#x000b1;&#x02009;12.4</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">75.5&#x02009;&#x000b1;&#x02009;11.2</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.02 (&#x02212;0.05 to 0.09)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.600</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KOOS pain</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">60.0&#x02009;&#x000b1;&#x02009;13.1</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">75.0&#x02009;&#x000b1;&#x02009;12.0</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">75.6&#x02009;&#x000b1;&#x02009;16.9</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">78.2&#x02009;&#x000b1;&#x02009;17.3</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">75.8&#x02009;&#x000b1;&#x02009;17.3</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">75.4&#x02009;&#x000b1;&#x02009;16.5</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.05 (&#x02212;0.04 to 0.12)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.186</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KOOS ADL</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">59.7&#x02009;&#x000b1;&#x02009;14.8</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">75.2&#x02009;&#x000b1;&#x02009;12.6</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">76.1&#x02009;&#x000b1;&#x02009;14.2</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">78.2&#x02009;&#x000b1;&#x02009;14.9</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">75.2&#x02009;&#x000b1;&#x02009;15.5</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">74.7&#x02009;&#x000b1;&#x02009;16.5</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.04 (&#x02212;0.04 to 0.12)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.309</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KOOS sport</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">50.3&#x02009;&#x000b1;&#x02009;14.2</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">66.0&#x02009;&#x000b1;&#x02009;13.9</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">68.7&#x02009;&#x000b1;&#x02009;20.0</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">68.9&#x02009;&#x000b1;&#x02009;19.6</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">64.6&#x02009;&#x000b1;&#x02009;19.5</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">65.4&#x02009;&#x000b1;&#x02009;17.8</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.02 (&#x02212;0.07 to 0.11)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.697</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KOOS QoL</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">52.1&#x02009;&#x000b1;&#x02009;12.4</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">66.7&#x02009;&#x000b1;&#x02009;15.8</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">67.9&#x02009;&#x000b1;&#x02009;20.7</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">69.2&#x02009;&#x000b1;&#x02009;18.1</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">65.6&#x02009;&#x000b1;&#x02009;16.0</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">65.4&#x02009;&#x000b1;&#x02009;15.4</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.02 (&#x02212;0.08 to 0.11)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.704</td></tr><tr><td colspan="9" align="left" valign="top" rowspan="1">Age&#x02009;&#x0003e; 60</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="char" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VAS</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">6.70&#x02009;&#x000b1;&#x02009;1.49</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">3.30&#x02009;&#x000b1;&#x02009;1.12</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">3.10&#x02009;&#x000b1;&#x02009;1.37</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">3.10&#x02009;&#x000b1;&#x02009;1.45</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">3.30&#x02009;&#x000b1;&#x02009;1.64</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">3.30&#x02009;&#x000b1;&#x02009;1.64</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">&#x02212;0.02 (&#x02212;0.04 to &#x02212;0.00)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.016</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TEGNER</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">67.8&#x02009;&#x000b1;&#x02009;7.1</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">79.2&#x02009;&#x000b1;&#x02009;7.1</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">78.4&#x02009;&#x000b1;&#x02009;6.8</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">79.1&#x02009;&#x000b1;&#x02009;7.1</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">78.4&#x02009;&#x000b1;&#x02009;7.4</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">78.4&#x02009;&#x000b1;&#x02009;7.4</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.07 (0.01&#x02013;0.13)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.025</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KOOS symptoms</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">60.0&#x02009;&#x000b1;&#x02009;10.9</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">72.2&#x02009;&#x000b1;&#x02009;13.9</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">75.3&#x02009;&#x000b1;&#x02009;11.6</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">75.7&#x02009;&#x000b1;&#x02009;8.4</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">70.5&#x02009;&#x000b1;&#x02009;9.4</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">72.9&#x02009;&#x000b1;&#x02009;7.7</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.09 (&#x02212;0.02 to 0.20)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.106</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KOOS pain</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">51.1&#x02009;&#x000b1;&#x02009;11.0</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">65.0&#x02009;&#x000b1;&#x02009;12.4</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">69.7&#x02009;&#x000b1;&#x02009;8.0</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">71.7&#x02009;&#x000b1;&#x02009;10.9</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">70.0&#x02009;&#x000b1;&#x02009;13.6</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">69.4&#x02009;&#x000b1;&#x02009;14.0</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.17 (0.05&#x02013;0.29)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KOOS ADL</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">53.8&#x02009;&#x000b1;&#x02009;7.0</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">64.6&#x02009;&#x000b1;&#x02009;9.5</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">65.2&#x02009;&#x000b1;&#x02009;7.8</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">67.4&#x02009;&#x000b1;&#x02009;9.2</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">67.6&#x02009;&#x000b1;&#x02009;9.4</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">67.6&#x02009;&#x000b1;&#x02009;9.4</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.13 (0.05&#x02013;0.21)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KOOS sport</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">43.0&#x02009;&#x000b1;&#x02009;11.1</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">57.5&#x02009;&#x000b1;&#x02009;12.3</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">60.0&#x02009;&#x000b1;&#x02009;13.3</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">61.0&#x02009;&#x000b1;&#x02009;11.5</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">60.5&#x02009;&#x000b1;&#x02009;10.7</td><td align="left" valign="top" rowspan="1" colspan="1">60.510.7</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.14 (0.05&#x02013;0.24)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KOOS QoL</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">40.0&#x02009;&#x000b1;&#x02009;12.6</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">53.1&#x02009;&#x000b1;&#x02009;15.1</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">56.9&#x02009;&#x000b1;&#x02009;11.2</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">61.3&#x02009;&#x000b1;&#x02009;10.5</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">60.6&#x02009;&#x000b1;&#x02009;11.8</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">60.6&#x02009;&#x000b1;&#x02009;11.8</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.22 (0.09&#x02013;0.34)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.001</td></tr></tbody></table><table-wrap-foot><fn id="jeo270144-tbl2-note-0001"><p>Abbreviations: ADL, activity of daily living; CI, confidence interval; KOOS, Knee Injury and Osteoarthritis Outcome; QoL, quality of life; VAS, visual analogue scale.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>When stratified for KL grade, two groups were formed: mild OA, hence KL I&#x02013;II (21 patients, of which 2 underwent TKA before 12 months and before the latest follow&#x02010;up, respectively) and moderate/severe OA; hence, KL III&#x02013;IV (20 patients, of which 1 underwent TKA before 12 months). Those with lower KL grades showed statistically significant changes for all categories apart from the Tegner score (Table&#x000a0;<xref rid="jeo270144-tbl-0003" ref-type="table">3</xref>).</p><table-wrap position="float" id="jeo270144-tbl-0003" content-type="Table"><label>Table 3</label><caption><p>The multilevel mixed&#x02010;effects regression analysis represents the change in clinical scores during the follow&#x02010;up period. Results were stratified according to Kallgren&#x02013;Lawrence (KL) in up to mild (1&#x02013;2) and moderate&#x02010;severe (3&#x02013;4) knee OA classification.</p></caption><table frame="hsides" rules="groups"><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="char" char="." style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000" valign="bottom"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Preoperative</th><th align="left" valign="bottom" rowspan="1" colspan="1">3 months</th><th align="left" valign="bottom" rowspan="1" colspan="1">6 months</th><th align="left" valign="bottom" rowspan="1" colspan="1">12 months</th><th align="left" valign="bottom" rowspan="1" colspan="1">24 months</th><th align="left" valign="bottom" rowspan="1" colspan="1">48 months</th><th align="left" valign="bottom" rowspan="1" colspan="1">Coeff (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td colspan="9" align="left" valign="top" rowspan="1">KL 1&#x02013;2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">21</td><td align="left" valign="top" rowspan="1" colspan="1">21</td><td align="left" valign="top" rowspan="1" colspan="1">21</td><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="left" valign="top" rowspan="1" colspan="1">19</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VAS</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">5.29&#x02009;&#x000b1;&#x02009;1.55</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">1.86&#x02009;&#x000b1;&#x02009;1.59</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">1.86&#x02009;&#x000b1;&#x02009;1.68</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">1.90&#x02009;&#x000b1;&#x02009;1.62</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">2.25&#x02009;&#x000b1;&#x02009;1.68</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">2.26&#x02009;&#x000b1;&#x02009;1.41</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">&#x02212;0.01 (&#x02212;0.02 to &#x02212;0.00)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.048</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TEGNER</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">71.5&#x02009;&#x000b1;&#x02009;8.7</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">86.3&#x02009;&#x000b1;&#x02009;9.4</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">85.7&#x02009;&#x000b1;&#x02009;9.6</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">85.2&#x02009;&#x000b1;&#x02009;9.0</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">83.6&#x02009;&#x000b1;&#x02009;9.2</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">84.4&#x02009;&#x000b1;&#x02009;7.3</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.04 (&#x02212;0.01 to 0.10)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.146</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KOOS symptoms</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">69.6&#x02009;&#x000b1;&#x02009;15.6</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">80.6&#x02009;&#x000b1;&#x02009;14.8</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">81.0&#x02009;&#x000b1;&#x02009;15.0</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">82.1&#x02009;&#x000b1;&#x02009;12.7</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">80.7&#x02009;&#x000b1;&#x02009;12.1</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">82.0&#x02009;&#x000b1;&#x02009;11.5</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.07 (0.01&#x02013;0.12)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.024</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KOOS pain</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">62.6&#x02009;&#x000b1;&#x02009;12.6</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">78.8&#x02009;&#x000b1;&#x02009;14.4</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">79.8&#x02009;&#x000b1;&#x02009;12.9</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">80.8&#x02009;&#x000b1;&#x02009;11.9</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">78.9&#x02009;&#x000b1;&#x02009;12.4</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">80.1&#x02009;&#x000b1;&#x02009;11.7</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.09 (0.02&#x02013;0.16)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KOOS ADL</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">62.2&#x02009;&#x000b1;&#x02009;13.6</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">75.6&#x02009;&#x000b1;&#x02009;13.5</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">76.4&#x02009;&#x000b1;&#x02009;13.8</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">78.2&#x02009;&#x000b1;&#x02009;12.9</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">76.1&#x02009;&#x000b1;&#x02009;14.0</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">77.9&#x02009;&#x000b1;&#x02009;13.8</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.09 (0.03&#x02013;0.15)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KOOS sport</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">53.3&#x02009;&#x000b1;&#x02009;16.5</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">68.8&#x02009;&#x000b1;&#x02009;14.7</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">70.7&#x02009;&#x000b1;&#x02009;16.1</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">70.8&#x02009;&#x000b1;&#x02009;15.8</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">68.8&#x02009;&#x000b1;&#x02009;15.6</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">70.5&#x02009;&#x000b1;&#x02009;13.9</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.08 (0.01&#x02013;0.15)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.028</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KOOS QoL</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">55.1&#x02009;&#x000b1;&#x02009;16.4</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">69.0&#x02009;&#x000b1;&#x02009;17.7</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">72.0&#x02009;&#x000b1;&#x02009;17.1</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">73.1&#x02009;&#x000b1;&#x02009;14.1</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">70.0&#x02009;&#x000b1;&#x02009;12.9</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">72.0&#x02009;&#x000b1;&#x02009;12.9</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.09 (0.01&#x02013;0.17)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.028</td></tr><tr><td colspan="9" align="left" valign="top" rowspan="1">KL 3&#x02013;4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="left" valign="top" rowspan="1" colspan="1">19</td><td align="left" valign="top" rowspan="1" colspan="1">19</td><td align="left" valign="top" rowspan="1" colspan="1">19</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VAS</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">6.35&#x02009;&#x000b1;&#x02009;1.57</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">2.60&#x02009;&#x000b1;&#x02009;1.31</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">2.60&#x02009;&#x000b1;&#x02009;1.90</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">2.63&#x02009;&#x000b1;&#x02009;1.80</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">3.32&#x02009;&#x000b1;&#x02009;1.73</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">3.53&#x02009;&#x000b1;&#x02009;1.65</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">&#x02212;0.01 (&#x02212;0.02 to 0.01)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.360</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TEGNER</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">70.3&#x02009;&#x000b1;&#x02009;9.3</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">83.8&#x02009;&#x000b1;&#x02009;7.7</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">83.7&#x02009;&#x000b1;&#x02009;9.2</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">82.8&#x02009;&#x000b1;&#x02009;9.5</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">80.4&#x02009;&#x000b1;&#x02009;8.3</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">80.1&#x02009;&#x000b1;&#x02009;8.2</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.01 (&#x02212;0.04 to 0.06)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.602</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KOOS symptoms</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">62.3&#x02009;&#x000b1;&#x02009;9.2</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">74.0&#x02009;&#x000b1;&#x02009;10.3</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">76.6&#x02009;&#x000b1;&#x02009;12.3</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">75.9&#x02009;&#x000b1;&#x02009;11.2</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">70.8&#x02009;&#x000b1;&#x02009;11.3</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">71.8&#x02009;&#x000b1;&#x02009;10.8</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.02 (&#x02212;0.05 to 0.08)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.623</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KOOS pain</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">54.7&#x02009;&#x000b1;&#x02009;12.2</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">70.4&#x02009;&#x000b1;&#x02009;11.3</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">71.8&#x02009;&#x000b1;&#x02009;14.5</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">73.1&#x02009;&#x000b1;&#x02009;16.4</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">70.2&#x02009;&#x000b1;&#x02009;16.2</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">68.4&#x02009;&#x000b1;&#x02009;15.7</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.06 (&#x02212;0.02 to 0.13)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.148</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KOOS ADL</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">57.6&#x02009;&#x000b1;&#x02009;11.1</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">71.8&#x02009;&#x000b1;&#x02009;11.5</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">71.9&#x02009;&#x000b1;&#x02009;12.7</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">72.9&#x02009;&#x000b1;&#x02009;14.0</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">71.0&#x02009;&#x000b1;&#x02009;12.9</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">69.3&#x02009;&#x000b1;&#x02009;13.5</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.04 (&#x02212;0.03 to 0.10)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.266</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KOOS sport</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">49.3&#x02009;&#x000b1;&#x02009;14.1</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">65.0&#x02009;&#x000b1;&#x02009;16.0</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">65.8&#x02009;&#x000b1;&#x02009;18.9</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">66.6&#x02009;&#x000b1;&#x02009;16.4</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">63.7&#x02009;&#x000b1;&#x02009;16.6</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">62.6&#x02009;&#x000b1;&#x02009;16.7</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.04 (&#x02212;0.03 to 0.12)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.289</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KOOS QoL</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">48.4&#x02009;&#x000b1;&#x02009;13.7</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">62.5&#x02009;&#x000b1;&#x02009;16.5</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">63.1&#x02009;&#x000b1;&#x02009;17.1</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">64.1&#x02009;&#x000b1;&#x02009;14.9</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">62.5&#x02009;&#x000b1;&#x02009;15.2</td><td align="char" char="&#x000b1;" valign="top" rowspan="1" colspan="1">61.2&#x02009;&#x000b1;&#x02009;15.1</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.06 (&#x02212;0.02 to 0.14)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.160</td></tr></tbody></table><table-wrap-foot><fn id="jeo270144-tbl3-note-0001"><p>Abbreviations: ADL, activity of daily living; CI, confidence interval; KOOS, Knee Injury and Osteoarthritis Outcome; OA, osteoarthritis; QoL, quality of life; VAS, visual analogue scale.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>The only post&#x02010;operative complication reported was the abdominal haematoma observed in 11 patients which self&#x02010;resolved within the first month.</p><p>The failure rate was assessed as well. Three patients underwent knee replacement surgery during the time of the study, specifically two patients before 12 months and one patient after 24 months of follow&#x02010;up time point.</p></sec><sec sec-type="discussion" id="jeo270144-sec-0160"><title>DISCUSSION</title><p>The main finding of the present prospective clinical trial is that a single intra&#x02010;articular injection of micro&#x02010;fragmented adipose tissue following knee arthroscopic debridement offers significant amelioration in clinical scores and a low failure rate up to 4 years of follow&#x02010;up.</p><p>The rationale behind the present study lies in the potential of MSCs in restoring and regenerate damaged tissues [<xref rid="jeo270144-bib-0029" ref-type="bibr">29</xref>]. MSCs are naturally found in most vascularized tissue, although the most common harvesting sites in clinical practice are adipose tissue, bone marrow or foetal annexes [<xref rid="jeo270144-bib-0016" ref-type="bibr">16</xref>, <xref rid="jeo270144-bib-0028" ref-type="bibr">28</xref>]. Despite some attempts to establish the optimum in terms of the quality of the tissue; nowadays, the available literature is not unanimous on the best harvesting site [<xref rid="jeo270144-bib-0019" ref-type="bibr">19</xref>, <xref rid="jeo270144-bib-0044" ref-type="bibr">44</xref>]. However, in vitro studies demonstrated that adipose tissue can contain up to 300&#x02010;fold the number of MSCs when compared to the same volume of bone marrow aspirate [<xref rid="jeo270144-bib-0004" ref-type="bibr">4</xref>, <xref rid="jeo270144-bib-0031" ref-type="bibr">31</xref>]. Moreover, adipose tissue harvesting is considered an easy and reproducible procedure by most surgeons, with a low intraoperative complication rate and an even lower rate of post&#x02010;operative adverse events [<xref rid="jeo270144-bib-0025" ref-type="bibr">25</xref>, <xref rid="jeo270144-bib-0040" ref-type="bibr">40</xref>, <xref rid="jeo270144-bib-0041" ref-type="bibr">41</xref>]. In our study, we reported no complications related to the procedure except for a minimal abdominal haematoma which self&#x02010;resolved in few days; furthermore, the minimal invasiveness of the procedure allowed the same&#x02010;day discharge with no post&#x02010;operative adverse events reported. This can be considered the direct consequence of the advent of one&#x02010;step procedures in the field of minimally manipulated products [<xref rid="jeo270144-bib-0015" ref-type="bibr">15</xref>]. In fact, given the restrictions currently applied in the field of manipulation of cells outside the operating room, the most common use of these products is possible thanks to regulatory shortcuts such as &#x02018;501k exemption&#x02019;, which allows to introduce in the market of new commercial kits if equivalent to those already in use, hence waiving the FDA approval [<xref rid="jeo270144-bib-0015" ref-type="bibr">15</xref>, <xref rid="jeo270144-bib-0022" ref-type="bibr">22</xref>]. The clear advantage of a one&#x02010;step procedure is however counterbalanced by the lack of standardization and the impossibility of a clear quality assessment of the tissue harvested. Nonetheless, beyond those limits, the role of MSCs for OA has been extensively proven to counteract inflammatory status and eventually promote regeneration of the tissues [<xref rid="jeo270144-bib-0010" ref-type="bibr">10</xref>] and data regarding both preclinical and clinical effects are starting to build strong scientific evidence. In vitro studies demonstrated how MSCs co&#x02010;cultured with human chondrocytes were able to stimulate proliferation and collagen formation [<xref rid="jeo270144-bib-0035" ref-type="bibr">35</xref>]. Furthermore, clinical outcomes collected by a recent meta&#x02010;analysis testified to the safety and good clinical outcomes of adipose&#x02010;derived mesenchymal cells for the treatment of knee OA [<xref rid="jeo270144-bib-0001" ref-type="bibr">1</xref>]. When addressing specific preparation kits, such as the Lipogems&#x000ae; used in the present study, clinical results found in the literature are comparable to the results of our trial. In particular, Bistolfi et al. reported that intraarticular autologous adipose tissue injection in patients with knee OA, KL Grades I&#x02013;III, reduced knee pain and stiffness. Patients gained improved knee function and experienced a better QoL in daily and sports activities with the absence of severe complications [<xref rid="jeo270144-bib-0008" ref-type="bibr">8</xref>]. The average follow&#x02010;up was 23.5 months, shorter than ours, although they presented a pool of 87 patients versus ours consisting of only 41 patients. Moreover, Schiavone Panni et al. also demonstrated an improvement in knee function scores and VAS pain scale on 52 patients with a mean follow&#x02010;up length of 15.3 months [<xref rid="jeo270144-bib-0039" ref-type="bibr">39</xref>]. The mean International Knee Society scoring system function improved from 37.4 pre&#x02010;operatively to 62.6 and the mean VAS decreased from 8.5 to 5.1 (134). It has also been observed that patients with VAS scores greater than 8 showed greater clinical and functional benefits as compared to those with VAS lower than 8. Barfod et al. also reached similar results as those obtained by our study. They followed up with 20 patients for up to 12 months on whom the Lipogems&#x000ae; system was used. The authors determined a statistically significant improvement in the KOOS for all subscales [<xref rid="jeo270144-bib-0006" ref-type="bibr">6</xref>]. Comparative studies of the micro&#x02010;fragmented adipose tissue injections with other injective options were also carried out, showing the potential of this treatment alternative. Richter et al. randomized 75 knee OA patients into three groups, consisting of corticosteroid injection, micro&#x02010;fragmented adipose tissue injection and saline injection. Clinical evaluation through Western Ontario and McMaster University Osteoarthritis Index and KOOS scores were conducted up to 1 year of follow&#x02010;up. The micro&#x02010;fragmented adipose tissue group demonstrated superiority compared to placebo up to 1 year, whereas the corticosteroids group was statistically significantly superior to placebo only up to 6 weeks of follow&#x02010;up [<xref rid="jeo270144-bib-0038" ref-type="bibr">38</xref>]. Zaffagnini et al. conducted a randomized controlled trial treating with micro&#x02010;fragmented adipose tissue injection or platelet&#x02010;rich plasma injection (PRP) with a total of 118 patients with symptomatic knee OA. They found statistically significant improvements in all clinical scores assessed up to 2 years of follow&#x02010;up, although no significant difference was found in terms of clinical or radiological response between the two treatment options. Interestingly, statistically significantly more patients in the micro&#x02010;fragmented adipose tissue group with moderate/severe OA reached the minimal clinically important difference for the International Knee Documentation Committee score at 6 months compared with the PRP group [<xref rid="jeo270144-bib-0043" ref-type="bibr">43</xref>]. Given the above&#x02010;mentioned scattered literature on the topic, we believe that the major strength of our study is the longer follow&#x02010;up period, being to our knowledge the first study in this setting to have assessed patients up to 48 months. Moreover, conducting a concomitant arthroscopy enabled us to evaluate the presence of disease different from OA which may have caused the symptoms. We are well aware of how a concomitant procedure apart from the intra&#x02010;articular injection could potentially offer a source of bias; however, this might be of minimal relevance considering how recent evidence is proving how the arthroscopy alone is not sufficient to provide symptom relief in knee OA [<xref rid="jeo270144-bib-0030" ref-type="bibr">30</xref>].</p><p>Furthermore, we believe that a further strength of this study is the stratification of the patients. When stratifying by age, patients older than 60 years achieved better clinical results compared to younger patients and this could be a game&#x02010;changer finding considering that this is usually the cluster of patients to whom a knee replacement is more often proposed. Conversely, statistical significance was obtained for patients with less severe radiological OA, suggesting that MSCs could better exert their role on functional outcomes when symptoms are caused by inflammation rather than bone&#x02010;to&#x02010;bone contact, confirming their significant anti&#x02010;inflammatory effect.</p><p>Nonetheless, this study suffers from several limitations. First, the limited sample size and the absence of a preliminary power calculation severely limit the impact of our findings. Accordingly, the lack of a control group is responsible for a confounding bias, since it is not possible to assess if the retrieved results are the consequence of our intervention or external factors. Furthermore, the absence of post&#x02010;operative imaging of any type can circumscribe our finding to a mere symptomatic relief and we were not able to assess any potential disease&#x02010;modifying effects on the disease progression.</p></sec><sec sec-type="conclusions" id="jeo270144-sec-0170"><title>CONCLUSIONS</title><p>A single intra&#x02010;articular knee injection of micro&#x02010;fragmented adipose tissue following arthroscopic debridement was able to provide significant clinical benefits in patients affected by knee OA for up to 4 years of follow&#x02010;up.</p></sec><sec id="jeo270144-sec-0180"><title>AUTHOR CONTRIBUTIONS</title><p>Andrea Antonio Maria Bruno, Enrico Arnaldi and Elizaveta Kon contributed to the study conception and design. Material preparation, data collection and analysis were performed by Massimo De Donato, Marco Basso, Jacopo Tamini and Paolo Dupplicato. The first draft of the manuscript was written by Andrea Antonio Maria Bruno. Giuseppe Anzillotti and Berardo Di Matteo contributed to the writing of the first draft. All the other authors conducted a critical review and editing of the final draft. All authors read and approved the final manuscript.</p></sec><sec sec-type="COI-statement" id="jeo270144-sec-0190"><title>CONFLICT OF INTEREST STATEMENT</title><p>Elizaveta Kon is a consultant for Zimmer Biomet, Smith &#x00026; Nephew, GreenBone, Geistlich Pharma, Fidia Farmaceutici, Mastelli and TerraQuantum, all not related to the present article. The remaining authors declare no conflicts of interest.</p></sec><sec id="jeo270144-sec-0220"><title>ETHICS STATEMENT</title><p>The internal Humanitas Research Hospital ethical committee approved the present study (study no. 2219). Written informed consent was obtained for all the patients included in the present study.</p></sec></body><back><sec sec-type="data-availability" id="jeo270144-sec-0210"><title>DATA AVAILABILITY STATEMENT</title><p>All the retrieved results are presented in the published paper. Raw data can be asked to the corresponding author, upon reasonable request.</p></sec><ref-list content-type="cited-references" id="jeo270144-bibl-0001"><title>REFERENCES</title><ref id="jeo270144-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jeo270144-cit-0001">
<string-name>
<surname>Agarwal</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Mak</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Bojanic</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>To</surname>, <given-names>K.</given-names>
</string-name> &#x00026; <string-name>
<surname>Khan</surname>, <given-names>W.</given-names>
</string-name> (<year>2021</year>) <article-title>Meta&#x02010;analysis of adipose tissue derived cell&#x02010;based therapy for the treatment of knee osteoarthritis</article-title>. <source>Cells</source>, <volume>10</volume>, <elocation-id>1365</elocation-id>. Available from: <pub-id pub-id-type="doi">10.3390/cells10061365</pub-id>
<pub-id pub-id-type="pmid">34206010</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jeo270144-cit-0002">
<string-name>
<surname>Altschuler</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Zaslav</surname>, <given-names>K.R.</given-names>
</string-name>, <string-name>
<surname>Di Matteo</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Sherman</surname>, <given-names>S.L.</given-names>
</string-name>, <string-name>
<surname>Gomoll</surname>, <given-names>A.H.</given-names>
</string-name>, <string-name>
<surname>Hacker</surname>, <given-names>S.A.</given-names>
</string-name> et al. (<year>2023</year>) <article-title>Aragonite&#x02010;based scaffold versus microfracture and debridement for the treatment of knee chondral and osteochondral lesions: results of a multicenter randomized controlled trial</article-title>. <source>The American Journal of Sports Medicine</source>, <volume>51</volume>, <fpage>957</fpage>&#x02013;<lpage>967</lpage>. Available from: <pub-id pub-id-type="doi">10.1177/03635465231151252</pub-id>
<pub-id pub-id-type="pmid">36779614</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jeo270144-cit-0003">
<string-name>
<surname>Anzillotti</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Conte</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Di Matteo</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Bertolino</surname>, <given-names>E.M.</given-names>
</string-name>, <string-name>
<surname>Marcacci</surname>, <given-names>M.</given-names>
</string-name> &#x00026; <string-name>
<surname>Kon</surname>, <given-names>E.</given-names>
</string-name> (<year>2022</year>) <article-title>Injection of biologic agents for treating severe knee osteoarthritis: is there a chance for a good outcome? A systematic review of clinical evidence</article-title>. <source>European Review for Medical and Pharmacological Sciences</source>, <volume>26</volume>, <fpage>5447</fpage>&#x02013;<lpage>5459</lpage>. Available from: <pub-id pub-id-type="doi">10.26355/eurrev_202208_29413</pub-id>
<pub-id pub-id-type="pmid">35993640</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jeo270144-cit-0004">
<string-name>
<surname>Aust</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Devlin</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Foster</surname>, <given-names>S.J.</given-names>
</string-name>, <string-name>
<surname>Halvorsen</surname>, <given-names>Y.D.C.</given-names>
</string-name>, <string-name>
<surname>Hicok</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>du Laney</surname>, <given-names>T.</given-names>
</string-name> et al. (<year>2004</year>) <article-title>Yield of human adipose&#x02010;derived adult stem cells from liposuction aspirates</article-title>. <source>Cytotherapy</source>, <volume>6</volume>, <fpage>7</fpage>&#x02013;<lpage>14</lpage>. Available from: <pub-id pub-id-type="doi">10.1080/14653240310004539</pub-id>
<pub-id pub-id-type="pmid">14985162</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jeo270144-cit-0005">
<string-name>
<surname>Aynardi</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Pulido</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Parvizi</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Sharkey</surname>, <given-names>P.F.</given-names>
</string-name> &#x00026; <string-name>
<surname>Rothman</surname>, <given-names>R.H.</given-names>
</string-name> (<year>2009</year>) <article-title>Early mortality after modern total hip arthroplasty</article-title>. <source>Clinical Orthopaedics &#x00026; Related Research</source>, <volume>467</volume>, <fpage>213</fpage>&#x02013;<lpage>218</lpage>. Available from: <pub-id pub-id-type="doi">10.1007/s11999-008-0528-5</pub-id>
<pub-id pub-id-type="pmid">18846410</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jeo270144-cit-0006">
<string-name>
<surname>Barfod</surname>, <given-names>K.W.</given-names>
</string-name> &#x00026; <string-name>
<surname>Bl&#x000f8;nd</surname>, <given-names>L.</given-names>
</string-name> (<year>2019</year>) <article-title>Treatment of osteoarthritis with autologous and microfragmented adipose tissue</article-title>. <source>Danish Medical Journal</source>, <volume>66</volume>, <fpage>A5565</fpage>.<pub-id pub-id-type="pmid">31571571</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jeo270144-cit-0007">
<string-name>
<surname>Bensa</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Salerno</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Boffa</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>de Girolamo</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Laver</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Magalon</surname>, <given-names>J.</given-names>
</string-name> et al. (<year>2024</year>) <article-title>Corticosteroid injections for the treatment of osteoarthritis present a wide spectrum of effects ranging from detrimental to disease&#x02010;modifying: a systematic review of preclinical evidence by the ESSKA Orthobiologic Initiative</article-title>. <source>Knee Surgery, Sports Traumatology, Arthroscopy</source>, <volume>32</volume>, <fpage>2725</fpage>&#x02013;<lpage>2745</lpage>. Available from: <pub-id pub-id-type="doi">10.1002/ksa.12242</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jeo270144-cit-0008">
<string-name>
<surname>Bistolfi</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Roato</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Fornelli</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Sabatini</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Mass&#x000e8;</surname>, <given-names>A.</given-names>
</string-name> &#x00026; <string-name>
<surname>Ferracini</surname>, <given-names>R.</given-names>
</string-name> (<year>2021</year>) <article-title>Treatment of knee osteoarthritis by intra&#x02010;articular injection of concentrated autologous adipose tissue: a twenty four month follow&#x02010;up study</article-title>. <source>International Orthopaedics</source>, <volume>45</volume>, <fpage>627</fpage>&#x02013;<lpage>633</lpage>. Available from: <pub-id pub-id-type="doi">10.1007/s00264-020-04923-0</pub-id>
<pub-id pub-id-type="pmid">33394073</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jeo270144-cit-0009">
<string-name>
<surname>Boffa</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Perucca Orfei</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Sourugeon</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Laver</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Magalon</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>S&#x000e1;nchez</surname>, <given-names>M.</given-names>
</string-name> et al. (<year>2023</year>) <article-title>Cell&#x02010;based therapies have disease&#x02010;modifying effects on osteoarthritis in animal models. A systematic review by the ESSKA Orthobiologic Initiative. Part 2: bone marrow&#x02010;derived cell&#x02010;based injectable therapies</article-title>. <source>Knee Surgery, Sports Traumatology, Arthroscopy</source>, <volume>31</volume>, <fpage>3230</fpage>&#x02013;<lpage>3242</lpage>. Available from: <pub-id pub-id-type="doi">10.1007/s00167-023-07320-3</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jeo270144-cit-0010">
<string-name>
<surname>Bora</surname>, <given-names>P.</given-names>
</string-name> &#x00026; <string-name>
<surname>Majumdar</surname>, <given-names>A.S.</given-names>
</string-name> (<year>2017</year>) <article-title>Adipose tissue&#x02010;derived stromal vascular fraction in regenerative medicine: a brief review on biology and translation</article-title>. <source>Stem Cell Research &#x00026; Therapy</source>, <volume>8</volume>, <fpage>145</fpage>. Available from: <pub-id pub-id-type="doi">10.1186/s13287-017-0598-y</pub-id>
<pub-id pub-id-type="pmid">28619097</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jeo270144-cit-0011">
<string-name>
<surname>Caplan</surname>, <given-names>A.I.</given-names>
</string-name> (<year>2010</year>) <article-title>What's in a name?</article-title>
<source>Tissue Engineering. Part A</source>, <volume>16</volume>, <fpage>2415</fpage>&#x02013;<lpage>2417</lpage>. Available from: <pub-id pub-id-type="doi">10.1089/ten.TEA.2010.0216</pub-id>
<pub-id pub-id-type="pmid">20412005</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jeo270144-cit-0012">
<string-name>
<surname>Caplan</surname>, <given-names>A.I.</given-names>
</string-name> (<year>2015</year>) <article-title>Adult mesenchymal stem cells: when, where, and how</article-title>. <source>Stem Cells International</source>, <volume>2015</volume>, <elocation-id>628767</elocation-id>. Available from: <pub-id pub-id-type="doi">10.1155/2015/628767</pub-id>
<pub-id pub-id-type="pmid">26273305</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jeo270144-cit-0013">
<string-name>
<surname>Cattaneo</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>De Caro</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Napoli</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Chiapale</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Trada</surname>, <given-names>P.</given-names>
</string-name> &#x00026; <string-name>
<surname>Camera</surname>, <given-names>A.</given-names>
</string-name> (<year>2018</year>) <article-title>Micro&#x02010;fragmented adipose tissue injection associated with arthroscopic procedures in patients with symptomatic knee osteoarthritis</article-title>. <source>BMC Musculoskeletal Disorders</source>, <volume>19</volume>, <fpage>176</fpage>. Available from: <pub-id pub-id-type="doi">10.1186/s12891-018-2105-8</pub-id>
<pub-id pub-id-type="pmid">29848328</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jeo270144-cit-0014">
<string-name>
<surname>D'Ambrosi</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Giacco</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Ragone</surname>, <given-names>V.</given-names>
</string-name> &#x00026; <string-name>
<surname>Ursino</surname>, <given-names>N.</given-names>
</string-name> (<year>2019</year>) <article-title>Arthroscopic treatment of osteochondral knee defects with resorbable biphasic synthetic scaffold: clinical and radiological results and long&#x02010;term survival analysis</article-title>. <source>International Orthopaedics</source>, <volume>43</volume>, <fpage>2183</fpage>&#x02013;<lpage>2189</lpage>. Available from: <pub-id pub-id-type="doi">10.1007/s00264-018-4270-7</pub-id>
<pub-id pub-id-type="pmid">30539223</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jeo270144-cit-0015">
<string-name>
<surname>Di Matteo</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Vandenbulcke</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Vitale</surname>, <given-names>N.D.</given-names>
</string-name>, <string-name>
<surname>Iacono</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Ashmore</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Marcacci</surname>, <given-names>M.</given-names>
</string-name> et al. (<year>2019</year>) <article-title>Minimally manipulated mesenchymal stem cells for the treatment of knee osteoarthritis: a systematic review of clinical evidence</article-title>. <source>Stem Cells International</source>, <volume>2019</volume>, <elocation-id>1735242</elocation-id>. Available from: <pub-id pub-id-type="doi">10.1155/2019/1735242</pub-id>
<pub-id pub-id-type="pmid">31485234</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jeo270144-cit-0016">
<string-name>
<surname>Di Matteo</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Anzillotti</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Gallese</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Vitale</surname>, <given-names>U.</given-names>
</string-name>, <string-name>
<surname>Gaggia</surname>, <given-names>G.M.M.C.</given-names>
</string-name>, <string-name>
<surname>Ronzoni</surname>, <given-names>F.L.</given-names>
</string-name> et al. (<year>2023</year>) <article-title>Placenta&#x02010;derived products demonstrate good safety profile and overall satisfactory outcomes for treating knee osteoarthritis: a systematic review of clinical evidence</article-title>. <source>Arthroscopy: The Journal of Arthroscopic &#x00026; Related Surgery</source>, <volume>39</volume>, <fpage>1892</fpage>&#x02013;<lpage>1904</lpage>. Available from: <pub-id pub-id-type="doi">10.1016/j.arthro.2023.03.033</pub-id>
<pub-id pub-id-type="pmid">37116549</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jeo270144-cit-0017">
<string-name>
<surname>Filardo</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Andriolo</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Angele</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Berruto</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Brittberg</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Condello</surname>, <given-names>V.</given-names>
</string-name> et al. (<year>2021</year>) <article-title>Scaffolds for knee chondral and osteochondral defects: indications for different clinical scenarios. a consensus statement</article-title>. <source>Cartilage</source>, <volume>13</volume>, <fpage>1036S</fpage>&#x02013;<lpage>1046S</lpage>. Available from: <pub-id pub-id-type="doi">10.1177/1947603519894729</pub-id>
<pub-id pub-id-type="pmid">31941355</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jeo270144-cit-0018">
<string-name>
<surname>Fusco</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Gambaro</surname>, <given-names>F.M.</given-names>
</string-name>, <string-name>
<surname>Di Matteo</surname>, <given-names>B.</given-names>
</string-name> &#x00026; <string-name>
<surname>Kon</surname>, <given-names>E.</given-names>
</string-name> (<year>2021</year>) <article-title>Injections in the osteoarthritic knee: a review of current treatment options</article-title>. <source>EFORT Open Reviews</source>, <volume>6</volume>, <fpage>501</fpage>&#x02013;<lpage>509</lpage>. Available from: <pub-id pub-id-type="doi">10.1302/2058-5241.6.210026</pub-id>
<pub-id pub-id-type="pmid">34267940</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jeo270144-cit-0019">
<string-name>
<surname>Gimble</surname>, <given-names>J.M.</given-names>
</string-name>, <string-name>
<surname>Katz</surname>, <given-names>A.J.</given-names>
</string-name> &#x00026; <string-name>
<surname>Bunnell</surname>, <given-names>B.A.</given-names>
</string-name> (<year>2007</year>) <article-title>Adipose&#x02010;derived stem cells for regenerative medicine</article-title>. <source>Circulation Research</source>, <volume>100</volume>, <fpage>1249</fpage>&#x02013;<lpage>1260</lpage>. Available from: <pub-id pub-id-type="doi">10.1161/01.RES.0000265074.83288.09</pub-id>
<pub-id pub-id-type="pmid">17495232</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jeo270144-cit-0020">
<string-name>
<surname>Glyn&#x02010;Jones</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Palmer</surname>, <given-names>A.J.R.</given-names>
</string-name>, <string-name>
<surname>Agricola</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Price</surname>, <given-names>A.J.</given-names>
</string-name>, <string-name>
<surname>Vincent</surname>, <given-names>T.L.</given-names>
</string-name>, <string-name>
<surname>Weinans</surname>, <given-names>H.</given-names>
</string-name> et al. (<year>2015</year>) <article-title>Osteoarthritis</article-title>. <source>The Lancet</source>, <volume>386</volume>, <fpage>376</fpage>&#x02013;<lpage>387</lpage>. Available from: <pub-id pub-id-type="doi">10.1016/S0140-6736(14)60802-3</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jeo270144-cit-0021">
<string-name>
<surname>Gress</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Charipova</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>An</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Hasoon</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Kaye</surname>, <given-names>A.D.</given-names>
</string-name>, <string-name>
<surname>Paladini</surname>, <given-names>A.</given-names>
</string-name> et al. (<year>2020</year>) <article-title>Treatment recommendations for chronic knee osteoarthritis</article-title>. <source>Best Practice &#x00026; Research. Clinical Anaesthesiology</source>, <volume>34</volume>, <fpage>369</fpage>&#x02013;<lpage>382</lpage>. Available from: <pub-id pub-id-type="doi">10.1016/j.bpa.2020.06.006</pub-id>
<pub-id pub-id-type="pmid">33004154</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jeo270144-cit-0022">
<string-name>
<surname>Hadley</surname>, <given-names>C.J.</given-names>
</string-name>, <string-name>
<surname>Shi</surname>, <given-names>W.J.</given-names>
</string-name>, <string-name>
<surname>Murphy</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Tjoumakaris</surname>, <given-names>F.P.</given-names>
</string-name>, <string-name>
<surname>Salvo</surname>, <given-names>J.P.</given-names>
</string-name> &#x00026; <string-name>
<surname>Freedman</surname>, <given-names>K.B.</given-names>
</string-name> (<year>2019</year>) <article-title>The clinical evidence behind biologic therapies promoted at annual orthopaedic meetings: a systematic review</article-title>. <source>Arthroscopy: The Journal of Arthroscopic &#x00026; Related Surgery</source>, <volume>35</volume>, <fpage>251</fpage>&#x02013;<lpage>259</lpage>. Available from: <pub-id pub-id-type="doi">10.1016/j.arthro.2018.05.037</pub-id>
<pub-id pub-id-type="pmid">30455088</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jeo270144-cit-0023">
<string-name>
<surname>Hiligsmann</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Cooper</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Arden</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Boers</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Branco</surname>, <given-names>J.C.</given-names>
</string-name>, <string-name>
<surname>Luisa Brandi</surname>, <given-names>M.</given-names>
</string-name> et al. (<year>2013</year>) <article-title>Health economics in the field of osteoarthritis: an expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)</article-title>. <source>Seminars in Arthritis and Rheumatism</source>, <volume>43</volume>, <fpage>303</fpage>&#x02013;<lpage>313</lpage>. Available from: <pub-id pub-id-type="doi">10.1016/j.semarthrit.2013.07.003</pub-id>
<pub-id pub-id-type="pmid">23992801</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jeo270144-cit-0024">
<string-name>
<surname>Hunter</surname>, <given-names>D.J.</given-names>
</string-name> &#x00026; <string-name>
<surname>Bierma&#x02010;Zeinstra</surname>, <given-names>S.</given-names>
</string-name> (<year>2019</year>) <article-title>Osteoarthritis</article-title>. <source>The Lancet</source>, <volume>393</volume>, <fpage>1745</fpage>&#x02013;<lpage>1759</lpage>. Available from: <pub-id pub-id-type="doi">10.1016/S0140-6736(19)30417-9</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jeo270144-cit-0025">
<string-name>
<surname>Koh</surname>, <given-names>Y.&#x02010;G.</given-names>
</string-name>, <string-name>
<surname>Choi</surname>, <given-names>Y.&#x02010;J.</given-names>
</string-name>, <string-name>
<surname>Kwon</surname>, <given-names>S.&#x02010;K.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>Y.&#x02010;S.</given-names>
</string-name> &#x00026; <string-name>
<surname>Yeo</surname>, <given-names>J.&#x02010;E.</given-names>
</string-name> (<year>2015</year>) <article-title>Clinical results and second&#x02010;look arthroscopic findings after treatment with adipose&#x02010;derived stem cells for knee osteoarthritis</article-title>. <source>Knee Surgery, Sports Traumatology, Arthroscopy</source>, <volume>23</volume>, <fpage>1308</fpage>&#x02013;<lpage>1316</lpage>. Available from: <pub-id pub-id-type="doi">10.1007/s00167-013-2807-2</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jeo270144-cit-0026">
<string-name>
<surname>Lee</surname>, <given-names>M.J.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>K.I.</given-names>
</string-name>, <string-name>
<surname>Shin</surname>, <given-names>J.M.</given-names>
</string-name>, <string-name>
<surname>Chae</surname>, <given-names>J.I.</given-names>
</string-name> &#x00026; <string-name>
<surname>Chung</surname>, <given-names>H.M.</given-names>
</string-name> (<year>2011</year>) <article-title>Enhancement of wound healing by secretory factors of endothelial precursor cells derived from human embryonic stem cells</article-title>. <source>Cytotherapy</source>, <volume>13</volume>, <fpage>165</fpage>&#x02013;<lpage>178</lpage>. Available from: <pub-id pub-id-type="doi">10.3109/14653249.2010.512632</pub-id>
<pub-id pub-id-type="pmid">21235296</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jeo270144-cit-0027">
<string-name>
<surname>Lopa</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Colombini</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Moretti</surname>, <given-names>M.</given-names>
</string-name> &#x00026; <string-name>
<surname>de Girolamo</surname>, <given-names>L.</given-names>
</string-name> (<year>2019</year>) <article-title>Injective mesenchymal stem cell&#x02010;based treatments for knee osteoarthritis: from mechanisms of action to current clinical evidences</article-title>. <source>Knee Surgery, Sports Traumatology, Arthroscopy</source>, <volume>27</volume>, <fpage>2003</fpage>&#x02013;<lpage>2020</lpage>. Available from: <pub-id pub-id-type="doi">10.1007/s00167-018-5118-9</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jeo270144-cit-0028">
<string-name>
<surname>Maqsood</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Kang</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Wu</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Teng</surname>, <given-names>L.</given-names>
</string-name> &#x00026; <string-name>
<surname>Qiu</surname>, <given-names>L.</given-names>
</string-name> (<year>2020</year>) <article-title>Adult mesenchymal stem cells and their exosomes: sources, characteristics, and application in regenerative medicine</article-title>. <source>Life Sciences</source>, <volume>256</volume>, <elocation-id>118002</elocation-id>. Available from: <pub-id pub-id-type="doi">10.1016/j.lfs.2020.118002</pub-id>
<pub-id pub-id-type="pmid">32585248</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jeo270144-cit-0029">
<string-name>
<surname>Muthu</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Jeyaraman</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Jain</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Gulati</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Jeyaraman</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Prajwal</surname>, <given-names>G.S.</given-names>
</string-name> et al. (<year>2021</year>) <article-title>Accentuating the sources of mesenchymal stem cells as cellular therapy for osteoarthritis knees&#x02014;a panoramic review</article-title>. <source>Stem Cell Investigation</source>, <volume>8</volume>, <fpage>13</fpage>. Available from: <pub-id pub-id-type="doi">10.21037/sci-2020-055</pub-id>
<pub-id pub-id-type="pmid">34386542</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jeo270144-cit-0030">
<string-name>
<surname>O'Connor</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Johnston</surname>, <given-names>R.V.</given-names>
</string-name>, <string-name>
<surname>Brignardello&#x02010;Petersen</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Poolman</surname>, <given-names>R.W.</given-names>
</string-name>, <string-name>
<surname>Cyril</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Vandvik</surname>, <given-names>P.O.</given-names>
</string-name> et al. (<year>2022</year>) <article-title>Arthroscopic surgery for degenerative knee disease (osteoarthritis including degenerative meniscal tears)</article-title>. <source>Cochrane Database of Systematic Reviews</source>, <volume>2022</volume>. Available from: <pub-id pub-id-type="doi">10.1002/14651858.CD014328</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jeo270144-cit-0031">
<string-name>
<surname>Oedayrajsingh&#x02010;Varma</surname>, <given-names>M.J.</given-names>
</string-name>, <string-name>
<surname>van Ham</surname>, <given-names>S.M.</given-names>
</string-name>, <string-name>
<surname>Knippenberg</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Helder</surname>, <given-names>M.N.</given-names>
</string-name>, <string-name>
<surname>Klein&#x02010;Nulend</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Schouten</surname>, <given-names>T.E.</given-names>
</string-name> et al. (<year>2006</year>) <article-title>Adipose tissue&#x02010;derived mesenchymal stem cell yield and growth characteristics are affected by the tissue&#x02010;harvesting procedure</article-title>. <source>Cytotherapy</source>, <volume>8</volume>, <fpage>166</fpage>&#x02013;<lpage>177</lpage>. Available from: <pub-id pub-id-type="doi">10.1080/14653240600621125</pub-id>
<pub-id pub-id-type="pmid">16698690</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jeo270144-cit-0032">
<string-name>
<surname>Pak</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>J.H.</given-names>
</string-name>, <string-name>
<surname>Pak</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Pak</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Park</surname>, <given-names>K.S.</given-names>
</string-name>, <string-name>
<surname>Jeon</surname>, <given-names>J.H.</given-names>
</string-name> et al. (<year>2018</year>) <article-title>Cartilage regeneration in humans with adipose tissue&#x02010;derived stem cells and adipose stromal vascular fraction cells: updated status</article-title>. <source>International Journal of Molecular Sciences</source>, <volume>19</volume>, <elocation-id>2146</elocation-id>. Available from: <pub-id pub-id-type="doi">10.3390/ijms19072146</pub-id>
<pub-id pub-id-type="pmid">30041472</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jeo270144-cit-0033">
<string-name>
<surname>Peretti</surname>, <given-names>G.M.</given-names>
</string-name>, <string-name>
<surname>Ulivi</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>De Girolamo</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Meroni</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Lombardo</surname>, <given-names>M.D.</given-names>
</string-name> &#x00026; <string-name>
<surname>Mangiavini</surname>, <given-names>L.</given-names>
</string-name> (<year>2018</year>) <article-title>Evaluation of the use of autologous micro&#x02010;fragmented adipose tissue in the treatment of knee osteoarthritis: preliminary results of a randomized controlled trial</article-title>. <source>Journal of Biological Regulators and Homeostatic Agents</source>, <volume>32</volume>, <fpage>193</fpage>&#x02013;<lpage>199</lpage>.<pub-id pub-id-type="pmid">30644302</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jeo270144-cit-0034">
<string-name>
<surname>Perucca Orfei</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Boffa</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Sourugeon</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Laver</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Magalon</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>S&#x000e1;nchez</surname>, <given-names>M.</given-names>
</string-name> et al. (<year>2023</year>) <article-title>Cell&#x02010;based therapies have disease&#x02010;modifying effects on osteoarthritis in animal models. A systematic review by the ESSKA Orthobiologic Initiative. Part 1: adipose tissue&#x02010;derived cell&#x02010;based injectable therapies</article-title>. <source>Knee Surgery, Sports Traumatology, Arthroscopy</source>, <volume>31</volume>, <fpage>641</fpage>&#x02013;<lpage>655</lpage>. Available from: <pub-id pub-id-type="doi">10.1007/s00167-022-07063-7</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jeo270144-cit-0035">
<string-name>
<surname>Pleumeekers</surname>, <given-names>M.M.</given-names>
</string-name>, <string-name>
<surname>Nimeskern</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Koevoet</surname>, <given-names>J.L.M.</given-names>
</string-name>, <string-name>
<surname>Karperien</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Stok</surname>, <given-names>K.S.</given-names>
</string-name> &#x00026; <string-name>
<surname>van Osch</surname>, <given-names>G.J.V.M.</given-names>
</string-name> (<year>2018</year>) <article-title>Trophic effects of adipose&#x02010;tissue&#x02010;derived and bone&#x02010;marrow&#x02010;derived mesenchymal stem cells enhance cartilage generation by chondrocytes in co&#x02010;culture</article-title>. <source>PLoS One</source>, <volume>13</volume>, <elocation-id>e0190744</elocation-id>. Available from: <pub-id pub-id-type="doi">10.1371/journal.pone.0190744</pub-id>
<pub-id pub-id-type="pmid">29489829</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="jeo270144-cit-0036">
<string-name>
<surname>Primorac</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Molnar</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Rod</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Jele&#x0010d;</surname>, <given-names>&#x0017d;.</given-names>
</string-name>, <string-name>
<surname>&#x0010c;ukelj</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Mati&#x00161;i&#x00107;</surname>, <given-names>V.</given-names>
</string-name> et al. (<year>2020</year>) <article-title>Knee osteoarthritis: a review of pathogenesis and state&#x02010;of&#x02010;the&#x02010;art non&#x02010;operative therapeutic considerations</article-title>. <source>Genes</source>, <volume>11</volume>, <elocation-id>854</elocation-id>. Available from: <pub-id pub-id-type="doi">10.3390/genes11080854</pub-id>
<pub-id pub-id-type="pmid">32722615</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="jeo270144-cit-0037">
<string-name>
<surname>Prince</surname>, <given-names>M.J.</given-names>
</string-name>, <string-name>
<surname>Wu</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Guo</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Gutierrez Robledo</surname>, <given-names>L.M.</given-names>
</string-name>, <string-name>
<surname>O'Donnell</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Sullivan</surname>, <given-names>R.</given-names>
</string-name> et al. (<year>2015</year>) <article-title>The burden of disease in older people and implications for health policy and practice</article-title>. <source>The Lancet</source>, <volume>385</volume>, <fpage>549</fpage>&#x02013;<lpage>562</lpage>. Available from: <pub-id pub-id-type="doi">10.1016/S0140-6736(14)61347-7</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="jeo270144-cit-0038">
<string-name>
<surname>Richter</surname>, <given-names>D.L.</given-names>
</string-name>, <string-name>
<surname>Harrison</surname>, <given-names>J.L.</given-names>
</string-name>, <string-name>
<surname>Faber</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Schrader</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Pierce</surname>, <given-names>C.</given-names>
</string-name> et al. (<year>2024</year>) <article-title>Microfragmented adipose tissue injection reduced pain compared with a saline control among patients with symptomatic osteoarthritis of the knee during 1&#x02010;year follow&#x02010;up: a randomized controlled trial</article-title>. <source>Arthroscopy: The Journal of Arthroscopic &#x00026; Related Surgery</source>. Available from: <pub-id pub-id-type="doi">10.1016/j.arthro.2024.08.037</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="jeo270144-cit-0039">
<string-name>
<surname>Schiavone Panni</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Vasso</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Braile</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Toro</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>De Cicco</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Viggiano</surname>, <given-names>D.</given-names>
</string-name> et al. (<year>2019</year>) <article-title>Preliminary results of autologous adipose&#x02010;derived stem cells in early knee osteoarthritis: identification of a subpopulation with greater response</article-title>. <source>International Orthopaedics</source>, <volume>43</volume>, <fpage>7</fpage>&#x02013;<lpage>13</lpage>. Available from: <pub-id pub-id-type="doi">10.1007/s00264-018-4182-6</pub-id>
<pub-id pub-id-type="pmid">30280218</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="jeo270144-cit-0040">
<string-name>
<surname>Ulivi</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Meroni</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Vigan&#x000f2;</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Colombini</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Lombardo</surname>, <given-names>M.D.M.</given-names>
</string-name>, <string-name>
<surname>Rossi</surname>, <given-names>N.</given-names>
</string-name> et al. (<year>2023</year>) <article-title>Micro&#x02010;fragmented adipose tissue (mFAT) associated with arthroscopic debridement provides functional improvement in knee osteoarthritis: a randomized controlled trial</article-title>. <source>Knee Surgery, Sports Traumatology, Arthroscopy</source>, <volume>31</volume>, <fpage>3079</fpage>&#x02013;<lpage>3090</lpage>. Available from: <pub-id pub-id-type="doi">10.1007/s00167-022-07101-4</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="jeo270144-cit-0041">
<string-name>
<surname>Van Genechten</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Vuylsteke</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Martinez</surname>, <given-names>P.R.</given-names>
</string-name>, <string-name>
<surname>Swinnen</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Sas</surname>, <given-names>K.</given-names>
</string-name> &#x00026; <string-name>
<surname>Verdonk</surname>, <given-names>P.</given-names>
</string-name> (<year>2021</year>) <article-title>Autologous micro&#x02010;fragmented adipose tissue (MFAT) to treat symptomatic knee osteoarthritis: early outcomes of a consecutive case series</article-title>. <source>Journal of Clinical Medicine</source>, <volume>10</volume>, <elocation-id>2231</elocation-id>. Available from: <pub-id pub-id-type="doi">10.3390/jcm10112231</pub-id>
<pub-id pub-id-type="pmid">34064010</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="jeo270144-cit-0042">
<string-name>
<surname>Yu</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Lu</surname>, <given-names>Q.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Sun</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>L.</given-names>
</string-name> et al. (<year>2023</year>) <article-title>Intra&#x02010;articular injection of autologous micro&#x02010;fragmented adipose tissue for the treatment of knee osteoarthritis: a prospective interventional study</article-title>. <source>Journal of Personalized Medicine</source>, <volume>13</volume>, <elocation-id>504</elocation-id>. Available from: <pub-id pub-id-type="doi">10.3390/jpm13030504</pub-id>
<pub-id pub-id-type="pmid">36983686</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="jeo270144-cit-0043">
<string-name>
<surname>Zaffagnini</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Andriolo</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Boffa</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Poggi</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Cenacchi</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Busacca</surname>, <given-names>M.</given-names>
</string-name> et al. (<year>2022</year>) <article-title>Microfragmented adipose tissue versus platelet&#x02010;rich plasma for the treatment of knee osteoarthritis: a prospective randomized controlled trial at 2&#x02010;year follow&#x02010;up</article-title>. <source>The American Journal of Sports Medicine</source>, <volume>50</volume>, <fpage>2881</fpage>&#x02013;<lpage>2892</lpage>. Available from: <pub-id pub-id-type="doi">10.1177/03635465221115821</pub-id>
<pub-id pub-id-type="pmid">35984721</pub-id>
</mixed-citation></ref><ref id="jeo270144-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="jeo270144-cit-0044">
<string-name>
<surname>Zuk</surname>, <given-names>P.A.</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Ashjian</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>De Ugarte</surname>, <given-names>D.A.</given-names>
</string-name>, <string-name>
<surname>Huang</surname>, <given-names>J.I.</given-names>
</string-name>, <string-name>
<surname>Mizuno</surname>, <given-names>H.</given-names>
</string-name> et al. (<year>2002</year>) <article-title>Human adipose tissue is a source of multipotent stem cells</article-title>. <source>Molecular Biology of the Cell</source>, <volume>13</volume>, <fpage>4279</fpage>&#x02013;<lpage>4295</lpage>. Available from: <pub-id pub-id-type="doi">10.1091/mbc.e02-02-0105</pub-id>
<pub-id pub-id-type="pmid">12475952</pub-id>
</mixed-citation></ref></ref-list></back></article>